• July 19, 2018

    Venom Immunotherapy Supplies

    Communication to Customers • May 16, 2018
    Read as letter
    Read related AAAAI/ACAAI email to members

    At the end of February, we learned that we will be the only supplier of venom immunotherapy products in North America. In light of this situation, we have evaluated our production capabilities as they relate to our ability to indefinitely supply the entire North American market. We determined that a substantial investment in equipment, facility and staff is necessary to ensure a long-term, consistent supply of venom extracts. However, we are confident that the supply of venom extracts will not be interrupted or reduced as a result of our competitor’s withdrawal from the market.

    We will continue to increase our production of venom extracts to minimize the chance of future shortages. We currently have sufficient supply, both on hand and in production, to meet the total U.S. demand. As a result, allergists should not hesitate to prescribe and maintain full dose venom immunotherapy at normal intervals, and resume treatment if treatment had been interrupted.

    As we continue to build our venom supply, we will focus on the production of our 5- and 12-dose products. These presentations allow us to build inventory at a faster rate than other presentations, which will help ensure we have enough doses to meet patient needs in the U.S. As we move forward we will continue to assess our production capabilities and the mix of venom presentations we produce.

    HollisterStier Allergy has, and will continue to be, your partner in subcutaneous immunotherapy. At the end of the day, our goal is to ensure patient safety through consistent supply of immunotherapy products. As always, we are grateful for your business and look forward to our continued partnership as your provider of allergy immunotherapy products.

  • January 26, 2018

    Chris Preti Joins Company as President

    Preti, ChrisJanuary 22, 2018 – Jubilant Pharma announces the appointment of Chris Preti to the position of President for its allergy company, HollisterStier Allergy.

    Mr. Preti has over 25 years of progressive pharmaceutical experience. He began his career at GlaxoSmithKline in research and development, developing products for regulatory submission across multiple therapeutic areas. He then joined Merck and its VIOXX new product marketing team in Rome, Italy.

    Upon returning to GSK, Mr. Preti joined a management development program and expanded his expertise across various commercial disciplines (marketing, sales & operations). He worked on critical products in the therapeutic fields of CNS and respiratory diseases with brands such as FLONASE and ADVAIR. Mr. Preti took on senior leadership roles across operations where he influenced marketing and sales effectiveness of over 4500 employees. In his most recent position, Mr. Preti was Vice President, COPD Marketing where he was fully responsible for the entire respiratory COPD portfolio of products, along with critical new launches.

    Mr. Preti holds a Masters of Science in Chemistry from Furman University, South Carolina and has also completed a Masters of International Business Studies at Darla Moore School of Business, South Carolina University along with Wharton’s School of Business Transformational Leadership program for executives in Pennsylvania.

    Mr. Preti and his family will be relocating to Spokane, WA from North Carolina.